Thromboembolic and Bleeding Risk During Anticoagulant Treatment in Asian Patents With Atrial Fibrillation
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 1,021
- 试验地点
- 2
- 主要终点
- Clinical ischemic and hemorrhagic events
研究概览
简要总结
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
详细描述
East Asians have demonstrated a higher bleeding tendency compared to Western populations during an anticoagulation. Consequently, East Asians have been prescribed as a relatively weaker treatment regimens based on this evidence. Therefore, the TARGET-AF study aims to verify the efficacy and safety of NOAC therapy using biomarkers including TEG®-6S point-of-care device in Koreans
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Months 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment.
- •Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months)
- •Adults aged 18 or above who have provided consent for clinical information
排除标准
- •Patients with moderate or severe mitral stenosis or mechanical prosthetic valve
结局指标
主要结局
Clinical ischemic and hemorrhagic events
时间窗: 12 months
The Rate of Ischemic stroke, systemic embolism, or myocardial infarction and ISTH (International Society on Thrombosis and Hemostasis) major/minor bleeding events
次要结局
- Clinical other events(12 months)
研究者
Ki-Woon Kang
Associate Professor
Chung-Ang University Hosptial, Chung-Ang University College of Medicine